Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
14
AKTX Quote, Financials, Valuation and Earnings
Last price:
$4.19
Seasonality move
:
-3.69%
Day range:
$4.16 - $4.80
52-week range:
$4.16 - $63.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.18x
Volume:
6.2K
Avg. volume:
12K
1-year change:
-89.84%
Market cap:
$5.1M
Revenue:
--
EPS (TTM):
-$0.39
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.80 | -- | -53.67% | $96.75 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.8M | -$0.66 | -21.74% | -24.99% | $12.67 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $7.02 |
|
CLLS
Cellectis SA
|
$10M | -$0.18 | -31.35% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$944.7K | -$0.14 | -- | -89.45% | $39.89 |
|
MREO
Mereo BioPharma Group Plc
|
$5.8M | $0.00 | -100% | -79.09% | $1.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
$4.47 | $96.75 | $5.1M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics Plc
|
$5.05 | $12.67 | $363.5M | -- | $0.00 | 0% | 4.82x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$0.87 | $7.02 | $1.1M | -- | $0.00 | 0% | 0.73x |
|
CLLS
Cellectis SA
|
$3.41 | $7.25 | $354.2M | -- | $0.00 | 0% | 4.70x |
|
DBVT
DBV Technologies SA
|
$21.06 | $39.89 | $1.2B | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group Plc
|
$0.32 | $1.73 | $49.3M | -- | $0.00 | 0% | 97.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
8.54% | 3.032 | 6.43% | 0.16x |
|
BCYC
Bicycle Therapeutics Plc
|
2.79% | 1.110 | 3.57% | 11.03x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 2.575 | -- | 1.20x |
|
CLLS
Cellectis SA
|
61.24% | 0.555 | 24.69% | 1.53x |
|
DBVT
DBV Technologies SA
|
11.39% | -0.562 | 2.4% | 3.35x |
|
MREO
Mereo BioPharma Group Plc
|
0.49% | 2.061 | 0.3% | 9.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics Plc
|
-- | -$2.2M | -82.27% | -91.86% | -- | -$2.1M |
|
BCYC
Bicycle Therapeutics Plc
|
$46.6M | -$31.1M | -31.56% | -32.03% | -64.9% | -$19.7M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
CLLS
Cellectis SA
|
$5.3M | -$18.8M | -31.08% | -65.19% | -181.22% | -$11M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$45.7M | -176.3% | -217.87% | -- | -$35.6M |
|
MREO
Mereo BioPharma Group Plc
|
-$591.1K | -$8.4M | -77.56% | -80.03% | -2099.86% | -$7.7M |
Akari Therapeutics Plc vs. Competitors
-
Which has Higher Returns AKTX or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of -42.03%. Akari Therapeutics Plc's return on equity of -91.86% beat Bicycle Therapeutics Plc's return on equity of -32.03%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M BCYCBicycle Therapeutics Plc97.21% -$0.29 $627.5M -
What do Analysts Say About AKTX or BCYC?
Akari Therapeutics Plc has a consensus price target of $96.75, signalling upside risk potential of 2064.43%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $12.67 which suggests that it could grow by 150.83%. Given that Akari Therapeutics Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Akari Therapeutics Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc3 0 0 BCYCBicycle Therapeutics Plc5 4 0 -
Is AKTX or BCYC More Risky?
Akari Therapeutics Plc has a beta of 0.532, which suggesting that the stock is 46.766% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.651, suggesting its more volatile than the S&P 500 by 65.123%.
-
Which is a Better Dividend Stock AKTX or BCYC?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or BCYC?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $47.9M. Akari Therapeutics Plc's net income of -$6.4M is higher than Bicycle Therapeutics Plc's net income of -$20.1M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 4.82x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M BCYCBicycle Therapeutics Plc4.82x -- $47.9M -$20.1M
-
Which has Higher Returns AKTX or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of --. Akari Therapeutics Plc's return on equity of -91.86% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AKTX or BDRX?
Akari Therapeutics Plc has a consensus price target of $96.75, signalling upside risk potential of 2064.43%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $7.02 which suggests that it could grow by 704.13%. Given that Akari Therapeutics Plc has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe Akari Therapeutics Plc is more attractive than Biodexa Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc3 0 0 BDRXBiodexa Pharmaceuticals Plc0 0 0 -
Is AKTX or BDRX More Risky?
Akari Therapeutics Plc has a beta of 0.532, which suggesting that the stock is 46.766% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.59%.
-
Which is a Better Dividend Stock AKTX or BDRX?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or BDRX?
Akari Therapeutics Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AKTX or CLLS?
Cellectis SA has a net margin of -- compared to Akari Therapeutics Plc's net margin of -253.13%. Akari Therapeutics Plc's return on equity of -91.86% beat Cellectis SA's return on equity of -65.19%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M CLLSCellectis SA50.92% -$0.26 $195.8M -
What do Analysts Say About AKTX or CLLS?
Akari Therapeutics Plc has a consensus price target of $96.75, signalling upside risk potential of 2064.43%. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Akari Therapeutics Plc has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics Plc is more attractive than Cellectis SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc3 0 0 CLLSCellectis SA2 1 0 -
Is AKTX or CLLS More Risky?
Akari Therapeutics Plc has a beta of 0.532, which suggesting that the stock is 46.766% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.
-
Which is a Better Dividend Stock AKTX or CLLS?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or CLLS?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.4M. Akari Therapeutics Plc's net income of -$6.4M is higher than Cellectis SA's net income of -$26.3M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 4.70x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M CLLSCellectis SA4.70x -- $10.4M -$26.3M
-
Which has Higher Returns AKTX or DBVT?
DBV Technologies SA has a net margin of -- compared to Akari Therapeutics Plc's net margin of --. Akari Therapeutics Plc's return on equity of -91.86% beat DBV Technologies SA's return on equity of -217.87%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M DBVTDBV Technologies SA-- -$1.17 $190.5M -
What do Analysts Say About AKTX or DBVT?
Akari Therapeutics Plc has a consensus price target of $96.75, signalling upside risk potential of 2064.43%. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that Akari Therapeutics Plc has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc3 0 0 DBVTDBV Technologies SA4 0 1 -
Is AKTX or DBVT More Risky?
Akari Therapeutics Plc has a beta of 0.532, which suggesting that the stock is 46.766% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.
-
Which is a Better Dividend Stock AKTX or DBVT?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or DBVT?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is higher than DBV Technologies SA's net income of -$44.8M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M DBVTDBV Technologies SA-- -- -- -$44.8M
-
Which has Higher Returns AKTX or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to Akari Therapeutics Plc's net margin of -2923.31%. Akari Therapeutics Plc's return on equity of -91.86% beat Mereo BioPharma Group Plc's return on equity of -80.03%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics Plc-- -$0.19 $24.8M MREOMereo BioPharma Group Plc14% -$0.05 $41.1M -
What do Analysts Say About AKTX or MREO?
Akari Therapeutics Plc has a consensus price target of $96.75, signalling upside risk potential of 2064.43%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $1.73 which suggests that it could grow by 446.71%. Given that Akari Therapeutics Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe Akari Therapeutics Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics Plc3 0 0 MREOMereo BioPharma Group Plc4 3 0 -
Is AKTX or MREO More Risky?
Akari Therapeutics Plc has a beta of 0.532, which suggesting that the stock is 46.766% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.788%.
-
Which is a Better Dividend Stock AKTX or MREO?
Akari Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or MREO?
Akari Therapeutics Plc quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. Akari Therapeutics Plc's net income of -$6.4M is higher than Mereo BioPharma Group Plc's net income of -$7.3M. Notably, Akari Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics Plc is -- versus 97.45x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics Plc-- -- -- -$6.4M MREOMereo BioPharma Group Plc97.45x -- -- -$7.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
